Search News Archives
Special Offers and Promotions
Conferences | Events
Evonetix expands facilities and relocates to central Cambridge, UK
15,000 sq. ft of laboratory and office space at Coldham’s Business Park will enable continued growth and development of the Company’s integrated desktop platform for DNA synthesis
EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, has announced it has moved to Coldham’s Business Park, Cambridge, UK. The new facility will enable the continued growth of the Company as it continues in its mission to develop a desktop DNA synthesis platform based on its proprietary silicon chip.
Evonetix, previously based at Chesterford Research Park, now occupies 15,000 square feet at Coldham’s Business Park, comprising 8,000 square feet of fully fitted and equipped state-of-the art laboratory space and 7,000 square feet of office space all under one roof. This enables the Company’s teams of physicists, electronics and software engineers, chemists, biologists and molecular biologists to work more closely together in a multidisciplinary approach to deliver the Evonetix mission. Headcount currently stands at 40, including 26 PhD biologists, physicists, chemists and engineers, and the Company is currently looking to recruit further staff, including biophysicists, electronics and protein engineers.
The Company’s silicon chip is made by MEMS processing and controls the synthesis of DNA at many thousands of independently controlled reaction sites or ‘pixels’ on the chip surface in a highly parallel fashion. This is compatible with both chemical and enzymatic DNA synthesis. Following synthesis, strands are assembled on-chip into double-stranded DNA in a process that identifies and removes errors, enabling accuracy, scale and speed that is several orders of magnitude better than conventional approaches.
Dr Tim Brears, Evonetix CEO, said: “Synthetic biology has the potential to solve some of the world’s most intractable problems, but we require innovation in gene synthesis to accelerate progress. Our new office and lab space will enable integration of our teams of specialists to support the development and delivery of our highly parallel desktop platform, which will be available to every researcher to accelerate their ability to use biology on a scale not currently possible.”